MONTREAL, June 16, 2025 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation, an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is ...

NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote ...

MENLO PARK, Calif., June 16, 2025 (GLOBE NEWSWIRE) -- Inquis Medical, the leading innovator in the treatment of venous thromboembolic disease, today announced that its AVENTUS Thrombectomy System has ...

AI meets genomics in BioAro’s latest launch, unlocking faster, scalable drug discovery. PanOmiQ™ Research sets a new global benchmark for precision health innovation.

The BIO International Convention provides an ideal platform to showcase how FibroBiologics is potentially transforming the treatment landscape for chronic diseases,” said Pete O’Heeron. “With our ...

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug ...

As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the “ Agreement ”) with a sophisticated investor (the “ Investor ”), pursuant to which ...

RESEARCH TRIANGLE PARK, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data on the long-term efficacy and safety of ORLADEYO ® (berotralstat) ...

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of June 2025, which is payable on ...

GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology . Phase 1 trial of MBX 4291 is exp ...

“Onco360 is grateful for the opportunity to partner with the team at Nuvation Bio and become a specialty pharmacy provider for IBTROZI,” said Benito Fernandez, Chief Commercial Officer at Onco360. “We ...

AD04 is Adial’s lead investigational drug, a serotonin-3 receptor antagonist, being developed for the treatment of Alcohol Use Disorder (AUD) in individuals with heavy drinking and select genotypes.